CHANGMAO BIO (00954) announced its interim results, with a loss attributable to shareholders of 4.932 million yuan, a decrease of 80.88% year-on-year.
Changmao Biological (00954) announced its interim results for the six months ending June 30, 2026, with revenue amounting to 290 million yuan, an increase of 6.34% year-on-year; the loss attributable to the company's shareholders for the period was 4.932 million yuan, a decrease of 80.88% year-on-year; loss per share was 0.009 yuan.
CHANGMAO BIO (00954) announced its interim results for the six months ended June 30, 2026, with revenue reaching 290 million yuan, an increase of 6.34% year-on-year; the loss attributable to shareholders of the company was 4.932 million yuan, a decrease of 80.88% year-on-year; loss per share was 0.009 yuan.
In the first half of the year, the company recorded a net loss attributable to shareholders of approximately 4.932 million yuan, a significant reduction of about 81% compared to the net loss of 25.79 million yuan in the same period last year, indicating a marked improvement in operational quality and continuing positive fundamentals.
Related Articles
CHINA POWER (02380) plans to sell a 24.8726% stake in Qiyuan Xindongli to Contemporary Amperex Technology for 2.2557 billion yuan.
EASY SMART GP (02442): The controlling shareholder, Tianfu International, transfers 25% of its shares to TC in exchange for a 45.88% equity stake in TC's subsidiary.
.png)
SHENGLONG INTL (08481) released its interim results, reporting a net loss of 10.517 million yuan.
CHINA POWER (02380) plans to sell a 24.8726% stake in Qiyuan Xindongli to Contemporary Amperex Technology for 2.2557 billion yuan.
EASY SMART GP (02442): The controlling shareholder, Tianfu International, transfers 25% of its shares to TC in exchange for a 45.88% equity stake in TC's subsidiary.
SHENGLONG INTL (08481) released its interim results, reporting a net loss of 10.517 million yuan.
RECOMMEND
